Introduction {#sec1}
============

Cell membranes are studded with glycoconjugates that provide a dense layer of glycans, the glycocalyx. This glycan coat comprises the glycans of glycolipids, proteoglycans and glycoproteins. Terminal glycan positions of mammalian glycoproteins and glycolipids are typically occupied by sialic acid ([@ref72]). The term sialic acid refers to a family of related, acidic monosaccharides. Their negative charge and exposed position predispose sialic acids for a major role in molecular and cellular interactions as they occur in physiological and pathological processes.

In the vascular system, sialic acid plays key roles in cell--cell and glycoprotein--protein interactions. In some of these processes, sialic acids are directly recognized and bound by specific glycan-binding proteins (GBP). In other instances, sialylation plays more indirect, modulatory roles, altering the molecular properties and interactions of the underlying protein.

In the present review, we first provide an overview over the functionally relevant properties of sialic acids and what is known about the regulation of sialylation. Many of the known functions of sialylation are related to the vascular system and its interactions with immune cells. We will thus mostly focus on the role of sialylation in biological processes related to vascular endothelia. For those that involve the direct recognition of sialic acids by GBP, a short overview is provided. Here, we give more room to the rarely discussed binding and signaling functions of vascular glycoproteins that are modulated by sialylation through other mechanisms.

Functionally relevant properties of sialic acids {#sec2}
------------------------------------------------

Sialic acids are a family of acidic monosaccharides characterized by a nine-carbon basic structure with a negatively charged carboxylate (C1) and a three-carbon exocyclic side chain (C7--C9). The sialic acids found in mammalian organisms vary in their substituent at C5, which in *N*-acetyl neuraminic acid (Neu5Ac) is an acetylated amino group, in *N*-glycolylneuraminic acid (Neu5Gc) a glycolylated amino group and in 2-keto-3-deoxy-nonulosonic acid (Kdn) a hydroxyl group.

The glycosidic linkage between the C2 of sialic acid and the underlying monosaccharide may be α2,3- or α2,6- to galactose (Gal) or *N*-acetylgalactosamine (GalNAc), or α2,8- to another sialic acid. The different linkages of sialic acid determine its steric configuration and the ability of the linkage to bend, rotate and adopt certain topologies upon binding ([@ref95]).

The type of sialic acid, further chemical modifications, as well as the configuration of the glycosidic linkage constitute stereospecific biophysical information that can be recognized by specific GBPs. The structure of the underlying glycan and the spatial organization of the sialylated glycans at the cell surface are additional factors that play important roles for the binding by GBPs and by GBP-expressing cells.

In mammals, sialic acids are very abundant and a single cell displays millions of sialic acid molecules ([@ref89]). Sialic acids contribute to the negative charge repulsion between cells and the regulation of cellular interactions ([@ref7]; [@ref89]). As an example, polysialic acid (a linear homopolymer of α2,8-linked sialic acids) on neural cell adhesion molecule (NCAM) increases the repulsion between cell membranes of adjacent cells and thus hinders NCAM- and cadherin-mediated intercellular adhesion ([@ref35]). Repulsion between sialylated glycans can also regulate the association and clustering of glycoproteins within the cell membrane and thus the avidity with which they bind their ligands (as described in the section \`\`lymphatic endothelial hyaluronan receptor-1\'\'). It can furthermore affect the binding affinity of sialylated glycoprotein ligands for their receptor. The presence of highly sialylated glycans on human erythropoietin (providing 5--10 sialic acids per molecule) reduces its binding velocity and affinity for the erythropoietin receptor. Electrostatic repulsion occurs between the sialic acids of erythropoietin and its negatively charged binding sites on the erythropoietin receptor ([@ref18]). Such repulsion involves long-range electrostatic forces and is due to the global electrostatic surface potential of sialylated erythropoietin. On the other hand, electrostatic interactions between sialic acids and positively charged amino acids of certain protein ligands may reinforce binding (described for the binding of vascular endothelial growth factor-A (VEGF-A) in the section \`\`Vascular endothelial growth factor receptor-2\'\'). The presence of sialic acids can also affect the intensity and duration of receptor-mediated signaling (described for the release of macrophage inflammatory protein-2 (MIP-2 or CXCL2) induced by soluble intercellular adhesion molecule-1 (sICAM-1) in the section \`\`Intercellular adhesion molecule-1\'\') or the serum half-life of a given sialo-glycoprotein. It has been shown that isoforms of erythropoietin carrying more heavily sialylated glycans have an increased serum half-life and are more active in stimulating the maturation of red blood cells in vivo ([@ref21]).

Sialylation and its regulation {#sec3}
------------------------------

Considering the multiple roles sialic acid may have in biological recognition and modulation of glycoprotein properties, it is of little surprise that sialylation is dynamically regulated in both developing and adult organisms ([@ref11]; [@ref68]; [@ref87]). The rate-limiting step in sialylation is the production of the activated sialic acid donor CMP-Sia. The sialic acid precursor Neu5Ac is formed in the cytosol by condensation of phosphoenolpyruvate with *N*-acetyl-mannosamine-6-phosphate (ManNAc-6-P). The latter is produced by the bifunctional glucosamine (uridine diphosphate (UDP)-*N*-acetyl)-2-epimerase/*N*-acetylmannosamine kinase, encoded by the gene GNE ([@ref30]; [@ref81]). CMP-Sia is then formed in the nucleus by CMP-Sia synthetase (CMAS) that transfers CMP to free sialic acid ([@ref76]). Rising cytosolic concentrations of CMP-Sia lead to an inhibition of the epimerization step catalyzed by GNE, which converts UDP-GlcNAc into free ManNAc ([@ref44]; [@ref79]). This is the main mechanism that regulates the amount of sialic acid that is produced in a cell ([@ref91]).

Sialylation of glycoconjugates occurs in the Golgi and is catalyzed by a family of 20 (human) sialyltransferases (STs) that can be subdivided into four families based on their glycan substrates and the sialic acid-linkage they form ([@ref27]). A first family comprises the six ST3Gal (ST3Gal1--ST3Gal6) that link sialic acid in α2,3-linkage to an underlying Gal residue. The ST6Gal family includes two members that form α2,6-linkages of sialic acid to an underlying Gal residue in *N-*glycans as well as extended *O*-glycans (ST6Gal1, ST6Gal2). Third, six members of the ST6GalNAc family catalyze addition of sialic acid in α2,6-linkage to an underlying GalNAc residue. The fourth family contains six members of ST8Sia, which attach sialic acids in α2,8-linkage to a terminal sialic acid ([@ref16]). The repertoire of STs expressed in a given cell defines in which linkage and to which glycoconjugates sialic acid is added. The expression level of STs (ST3Gal5, ST6Gal1 and ST6GalNAc4) was shown to inversely correlate with the availability of CMP-Sia ([@ref6]).

Another means to regulate the sialylation of glycoconjugates is the enzymatic removal of sialic acid by sialidases (formerly called neuraminidases). The mammalian genome encodes four sialidases that have similar tertiary conformations in spite of low amino acid sequence homology (NEU1--4; for recent review, see [@ref64]). The NEU differ in substrate specificity and cellular localization. NEU1 is most abundantly expressed in human tissues and has the lowest degree of homology to the other family members ([@ref28]). NEU1 is found in the lysosome and, after transport in exovesicles, also at the cell surface, where it exclusively acts on glycoproteins ([@ref5]; [@ref82]; [@ref53]). It hydrolyses α2,3-linkages of sialic acid more quickly than α2,6- or α2,8-linkages ([@ref58]).

Sialylation-function relationships of vascular glycoproteins that involve stereospecific recognition of sialylated glycan epitopes by glycan-binding proteins {#sec4}
=============================================================================================================================================================

Direct binding of carbohydrates by GBPs is important in various molecular interactions between vascular endothelial cells and leukocytes ([Figure 1](#f1){ref-type="fig"}). Such interactions are key to the dynamic regulation of the permeability of the vascular endothelium for blood-borne immune cells, thus allowing for immune responses to invading pathogens and injury. They are also crucial for adhesion of B- and T-lymphocytes to the high endothelial venules (HEVs) of peripheral lymph nodes and their homing to secondary lymphoid organs.

![Cell--cell interactions between immune cells and vascular endothelia that depend on sialylation are shown in their microanatomical context. Lymphatic vessels entering, within and exiting a peripheral lymph node as well as small arteries (left) and veins (right) joined by a capillary network are depicted. Immune cells interacting with different subtypes of endothelial cells in various anatomical locations as well as the glycoproteins involved in such interactions are shown in the enlarged image sections. (**A**) Molecular interactions that are involved in leukocyte extravasation from a peripheral blood capillary into inflamed or injured tissue are shown. In the initial tethering of a leukocyte to activated BECs, binding of a sialylated glycan epitope on PSGL-1 by endothelial selectins (such as P-selectin) plays a crucial role. The subsequent firm adhesion mediated by binding of the integrin LFA-1 to ICAM-1 does however not appear to depend on the glycosylation of ICAM-1. (**B**) Adhesive interactions of DC with LEC are involved in their transmigration from the tissue into lymphatic capillaries. Binding of HA-coated DC by LYVE-1 that is abundantly expressed on lymphatic capillaries may be involved in this process. HA binding only occurs when LYVE-1 is present in clusters and clustering appears to be regulated by the sialylation of *O*-glycans present in the stalk region of LYVE-1. (**C**) Molecular interactions that are involved in the homing of lymphocytes into the lymph node through the postcapillary HEVs. L-selectin present on the lymphocytes binds to sialylated glycan epitopes displayed on various glycoproteins such as GlyCAM-1 and CD34. Firm adhesion occurs by binding of LFA-1 expressed by lymphocytes to endothelial ICAM-1. (**D**) CLEC-2 expressed on DC binds to podoplanin, which is abundantly expressed by LEC. Such binding depends on the sialylation of *O*-glycans on podoplanin. This figure is available in black and white in print and in color at *Glycobiology* online.](cwaa008f1){#f1}

Endothelial cells line the lumens of blood and lymphatic vessels. Formation of cell--cell junctions between endothelial cells typically involves platelet endothelial cell adhesion molecule-1 (PECAM-1), which is used as a marker protein for endothelia. Blood vascular and lymphatic vascular endothelial cells (BECs and LECs) can be distinguished based on the expression of prospero-related homeobox-1 transcription factor (PROX-1) ([@ref92]), podoplanin ([@ref8]) and LYVE-1 ([@ref3]) by LECs. LECs and BECs are derived from the same embryonic precursor cells, the so-called angioblasts ([@ref2]). Differentiation of LECs from BECs in mice is hallmarked by the expression of PROX-1 on embryonic day 9.5 ([@ref86]). PROX-1 represses the expression of several blood vasculature-specific genes, but stimulates expression of genes that are associated with the lymphatic phenotype, such as LYVE-1 and podoplanin ([@ref31]; [@ref65]). LYVE-1 is an *N*- and *O*-glycosylated transmembrane glycoprotein and a receptor for hyaluronan (HA) helping to anchor LECs in the ECM. Podoplanin is a heavily *O*-glycosylated mucin-type glycoprotein. Its binding by C-type lectin-like receptor-2 (CLEC-2) on platelets leads to platelet activation and aggregation ([@ref85]). Podoplanin-mediated platelet aggregation is also a crucial step during separation of the lymphatic from the blood vasculature during embryonic development ([@ref88]).

The sialylated glycan epitopes bound by selectins {#sec6}
=================================================

The most thoroughly investigated protein--carbohydrate recognition within the vasculature involves the selectins and their sialylated binding partners. Their roles in extravasation of innate immune cells into inflamed tissues and in homing of lymphocytes to lymph nodes are not only a cornerstone of glycobiology, but also a central concept of immunology. For detailed descriptions of the selectins, their ligands and functions, we refer the reader to excellent reviews by others ([@ref52]; [@ref80]; [@ref73]). Here, we provide a brief overview and primarily focus on the role the sialylation of selectin ligands plays for selectin binding.

In the first step of leukocyte extravasation, the leukocytes are loosely tethered to the activated endothelial surface by the endothelial selectins and roll along the inner vessel wall ([Figure 1A](#f1){ref-type="fig"}) ([@ref25]). The major ligand of P-selectin on leukocytes is P-selectin glycoprotein ligand-1 (PSGL-1), a dimeric mucin-type transmembrane glycoprotein expressed by leukocytes ([Table I](#TB1){ref-type="table"}). The P-selectin binding site is located at the N-terminus of PSGL-1 and includes a core-2-based *O*-glycan capped with sialyl Lewis x (sLe^x^; Siaα2,3-Galβ1,4-(Fucα1,3)-GlcNAc). In PSGL-1-deficient mice, leukocyte rolling and recruitment mediated by P- but not E-selectin is dramatically reduced ([@ref96]). Thus, E-selectin appears to also bind other sLe^x^-carrying glycoconjugates. When it comes to binding of PSGL-1, E- and P-selectin behave differently. P-selectin displays much higher binding affinity than E-selectin and this is due to the additional contacts of basic amino acids with tyrosine sulfate residues of PSGL-1 ([@ref93]; [@ref48]). But when the binding affinities for sLe^x^ alone are compared, E-selectin displays 10-fold higher affinity ([@ref67]). Based on the crystal structure, this was explained by a more extensive set of hydrogen bonds formed between the carbohydrate recognition domain (CRD) of E-selectin and sLe^x^ ([@ref78]). It thus appears that E- and P-selectin have differing, specialized roles in leukocyte extravasation.

###### 

The molecular characteristics of vascular glycoproteins whose sialylated glycan epitopes are recognized by GBP

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ![](cwaa008fx1.jpg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  --------------------- ----------------------------------------------------------------- --------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------
  Names                 P-selectin glycoprotein ligand 1; Selectin P ligand               Hematopoietic progenitor cell antigen               Glycosylation-dependent cell adhesion molecule 1; Endothelial ligand for L-selectin; MC26; sulfated 50 kDa glycoprotein (SGP50)   Podocalyxin-like protein 1 (PC or PCLP-1); GCTM-2 antigen; Gp200;   Endomucin-2; Gastric cancer antigen; Ga34; Mucin-14 (MUC-14)   Mucosal addressin; cell adhesion molecule 1                        Aggrus; Glycoprotein 36 (Gp36); PA2.26 antigen; T1-alpha (T1A)

  CD antigen            CD162                                                             CD34                                                --                                                                                                                                --                                                                  --                                                             --                                                                 --

  Gene name             SELPG                                                             CD34                                                GLYCAM1                                                                                                                           PODXL                                                               EMCN                                                           MADCAM1                                                            PDPN

  Size                  h: 371 aa                                                         h: 354 aa\                                          m: 132 aa                                                                                                                         h: 536 aa\                                                          h: 243 aa\                                                     h: 364 aa\                                                         h: 152 aa\
                                                                                          m: 348 aa                                                                                                                                                                             m: 482 aa                                                           m: 241 aa                                                      m: 384 aa                                                          m: 150 aa

  *N*-glycans           h: 3                                                              h: 9\                                               m: 1                                                                                                                              h: 5\                                                               h: 6\                                                          h: 1\                                                              --\
                                                                                          m: 7                                                                                                                                                                                  m: 8                                                                m: 5                                                           m: 3                                                               m: 1

  O-glycosylation       Heavily O-glycosylated; core-2 *O*-glycan with sLe^x^ at Thr 57   Extensively O-glycosylated                          Extensively O-glycosylated                                                                                                        Highly O-glycosylated Thr-rich domain                               Highly O-glycosylated, Thr-rich domain                         Ser/Thr-rich mucin-like domain O-glycosylated                      h: 24 O-linked glycans\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      m: 18 O-linked glycans

  Ligands               P-, E- and L-selectin; Homodimer (disulfide-linked)               L-selectin                                          L-selectin                                                                                                                        L-selectin\                                                         L-selectin                                                     Homodimer; L-selectin                                              Homodimer; CLEC-2; CD9 (Tetraspanin) Galectin 8; HSPA9; CCL21; CD44 Moesin and Ezrin (via cytoplasmatic domain)
                                                                                                                                                                                                                                                                                CCR6\                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                Galectin-3\                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                Galectin-8\                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                Galectin-9\                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                Ficolin                                                                                                                                                                                               

  Cellular expression   Leukocytes                                                        Endothelial cells, hematopoietic progenitor cells   Endothelial cells (HEVs)                                                                                                          Endothelial cells, Glomerular podocytes, glandular cells            Endothelial cells                                              HEVs and endothelial cells in spleen and gastro-intestinal tract   Lymphatic endothelial cells, alveolar type-1 epithelial cells, T cells, macrophages, podocytes, fibroblastic reticular cells
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The human glycoproteins are depicted with the exception of GlyCAM-1, which is not found in human tissues. The information was gathered from the human protein atlas (<https://www.proteinatlas.org/>) and from uniprot (<https://www.uniprot.org/>).

An early observation was that sialidase treatment of neutrophils led to a dramatic reduction of P-selectin-dependent rolling in vivo ([@ref51]). More recently, it was shown that the sialyltransferases ST3Gal4 and ST3Gal6 are responsible for E- and P-selectin ligand formation ([@ref22]; [@ref97]). The neutrophils from mice deficient in both sialyltransferases displayed significantly reduced binding to E- and P-selectin.

In lymphocyte homing through the HEVs of lymph nodes, L-selectin expressed on the lymphocyte binds to its ligands on the endothelial cells ([Figure 1C](#f1){ref-type="fig"}). The ligands of L-selectin are collectively called peripheral node addressins (PNAd) and include glycans present on the vascular sialomucin CD34, the murine glycosylated cell adhesion molecule-1 (GlyCAM-1), podocalyxin, endomucin and MAdCAM ([Table I](#TB1){ref-type="table"}) ([@ref55]; [@ref70]). The members of the PNAd complex are functionally redundant and thus appear to mostly function as protein scaffolds for the presentation of glycan epitopes comprising sLe^x^ and sulfated versions thereof ([@ref57]). The 6-sulfo-sialyl Lewis x (6-sulfo-sLe^x^) is an L-selectin ligand with particularly high affinity. The HEVs of peripheral lymph nodes display higher expression levels of genes encoding sialyl-, fucosyl- and sulfotransferases (ST3GAL4, FUT7, Chst2 and most prominently Chst4) compared to the HEVs of Peyer's patches ([@ref47]). The lower expression of these genes in Peyer's patches is in line with earlier reports on low levels of L-selectin ligands that only allow for loose L-selectin-mediated rolling in Peyer's patches ([@ref10]).

The carbohydrate ligands of E- and P-selectin involved in tethering and rolling of leukocytes on activated BECs are expressed on the leukocytes, whereas the carbohydrate ligands of L-selectin involved in homing of lymphocytes to secondary lymphoid organs are presented on the HEVs ([@ref80]). The differing cellular distribution of selectin ligands involved in extravasation depending on the location and the processes they govern within the vasculature may be a means to increase their local and functional specificity. The expression of selectin ligands on different cell types may also explain why they occur on different membrane proteins and comprise differing glycan epitopes. In homing of B- and T-lymphocytes, L-selectin binds best to ligands that include not only sLe^x^, but also glycans containing 6-*O*-sulfated GlcNAc such as 6-sulfo sLe^x^ ([@ref29]). For leukocyte rolling under inflammatory conditions however, endothelial P- and E-selectin bind to sLe^x^ on the core-2-*O*-glycan at Thr57 of PSGL-1 ([@ref49]).

Podoplanin {#sec7}
==========

Another sialic acid-dependent interaction between blood cells and vascular endothelial cells is mediated by CLEC-2. CLEC-2 is expressed by platelets and myeloid cells (e.g. dendritic cells -- DC) and appears to have an exclusive binding specificity for its one known ligand, podoplanin ([Table I](#TB1){ref-type="table"}). Within the vasculature, podoplanin is expressed exclusively on LECs. Its binding by platelet CLEC-2 provokes platelet activation and aggregation ([@ref85]; [@ref41]), whereas interaction with CLEC-2 on DC is important in DC migration to lymph nodes ([@ref1]).

Initial studies on the role of glycosylation for the binding and activation of CLEC-2 were based on podoplanin expressed on different glycosylation mutants of CHO cells. Both human and mouse podoplanin induced aggregation of mouse platelets only when carrying sialylated *O*-glycans ([@ref40]). The glycans of human podoplanin expressed by CHO cells or the glioblastoma cell line LN319 were later shown to be di- or mono-sialylated core-1 *O*-glycans ([@ref38]). The CLEC-2 binding sites on human and mouse podoplanin were reported to be 47-EDDVVTPG-54 with a disialylated core-1 *O*-glycan at T52 and 29-EDDIVTPG-36 with a disialylated core-1 *O*-glycan at T34, respectively ([@ref39]). However, later studies based on site-directed mutagenesis and peptide deletions suggested that there may be an additional CLEC-2 binding site on podoplanin (81-EDLPTSE-87 of human podoplanin) that includes negatively charged amino acids and *O*-glycans ([@ref4]; [@ref75]).

Podoplanin was also found to interact with galectin-8 in a glycosylation-dependent manner. Galectin-8 is a tandem-repeat galectin with an N-terminal CRD-binding α2,3-sialylated glycans with high affinity and a C-terminal CRD that does not bind sialylated glycans ([@ref32]). Galectin-8 is expressed by LECs. It was suggested that the interaction of galectin-8 with podoplanin may contribute to the anchoring of the lymphatic endothelium to the surrounding extracellular matrix, most likely together with other surface glycoproteins of LECs ([@ref17]). Furthermore, galectin-8 was reported to mediate crosstalk among podoplanin, vascular endothelial growth factor-C (VEGF-C) and integrin-mediated pathways in pathological lymphangiogenesis in the eye ([@ref13]).

Vascular glycoproteins whose biological functions are modulated by sialylation {#sec8}
==============================================================================

Besides the famous examples of sialylated glycans that are specifically bound by GBPs, there are various reports on functional roles of sialylation within the vasculature that may rely on other mechanisms.

Intercellular adhesion molecule-1 {#sec9}
---------------------------------

One of the most widely studied vascular adhesion molecules is ICAM-1 ([Table II](#TB2){ref-type="table"}). Its expression on both LECs and BECs is normally low but strongly induced upon inflammatory activation ([@ref66]; [@ref37]). In parallel, a soluble form of ICAM-1 is released ([@ref71]; [@ref9]; [@ref61]; [@ref24]). The major role of membrane-bound ICAM-1 is to mediate the second step in the extravasation of immune cells into inflamed tissue occurring after the tethering and rolling mediated by P- and E-selectin, namely the firm adhesion and subsequent transmigration of leukocytes ([@ref25]; [@ref90]). The ICAM-1 binding partners in this process are the integrins leukocyte function-associated antigen-1 (LFA-1; CD11a/CD18; [Figure 1A](#f1){ref-type="fig"}) present on all leukocytes and macrophage antigen-1 (Mac-1; CD11b/CD18) on myeloid cells ([@ref54]; [@ref19]). The functional roles of soluble ICAM-1 (sICAM-1) are less clear. It was proposed on the one hand that it could influence the adhesive interactions between leukocytes and endothelial cells acting as a competitive inhibitor ([@ref69]; [@ref56]). On the other hand, sICAM-1 was found to act as a signaling molecule inducing secretion of the CXC chemokine MIP-2 (CXCL2) by both brain-derived mouse microvascular endothelial cells and astrocytes ([@ref61]).

###### 

The molecular characteristics of the vascular glycoproteins whose biological functions are modulated by sialylation

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ![](cwaa008fx2.jpg)                                                                                                                                                                                                                                                                                                       
  --------------------- -------------------------------------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein family        Ig-like domain superfamily                                           Ig-like domain superfamily                                            Ig-like domain superfamily; tyrosine kinase receptor                                                                                                     C-type lectin-like/link domain superfamily

  Names                 Intercellular adhesion molecule-1; Major group rhinovirus receptor   Platelet endothelial cell adhesion molecule; EndoCAM; GPIIA'; PECA1   Vascular endothelial growth factor receptor 2; Fetal liver kinase (FLK-1); Kinase insert domain receptor (KDR); Protein-tyrosine kinase receptor flk-1   Lymphatic vessel endothelial hyaluronic acid receptor 1; Cell surface retention sequence-binding protein 1 (CRSBP-1); Extracellular link domain-containing protein 1; Hyaluronic acid receptor

  CD antigen            CD54                                                                 CD31                                                                  CD309                                                                                                                                                    --

  Gene name             ICAM1                                                                PECAM1                                                                KDR                                                                                                                                                      LYVE1

  Size                  h: 505 aa\                                                           h: 711 aa\                                                            h: 1337 aa\                                                                                                                                              h: 303 aa\
                        m: 510 aa                                                            m: 710 aa                                                             m: 1348 aa                                                                                                                                               m: 295 aa

  *N*-glycans           h: 8\                                                                h: 7\                                                                 h: 18\                                                                                                                                                   h: 2\
                        m: 9                                                                 m: 9                                                                  m: 17                                                                                                                                                    m: 2

  O-glycosylation       ND                                                                   ND                                                                    ND                                                                                                                                                       Sialylated O-linked glycans in the Ser/Thr-rich stalk region

  Ligands               LFA-1 (CD11a/CD18), Mac-1 (CD11b/CD18) MUC1 CD81, CD247, CD9         PECAM-1 (*trans*-homodimer)                                           VEGF-A, VEGF-C and VEGF-D Forms homodimer or heterodimers with VEGFR-1 and VEGFR3                                                                        LYVE-1 (disulfide-linked homodimer); hyaluronan

  Cell expression       Endothelial cells, pneumocytes and subsets of lymphoid cells.        Endothelial cells and smooth muscle cells.                            Endothelial cells                                                                                                                                        Lymphatic endothelial cells and macrophage subsets
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The human glycoproteins are depicted. The information was gathered from the human protein atlas (<https://www.proteinatlas.org/>) and from uniprot (<https://www.uniprot.org/>). ND, not determined.

Glycosylation affects the different functions of ICAM-1 differentially. Binding to LFA-1 is not influenced by glycosylation of both, human and mouse ICAM-1 ([@ref20]; [@ref62]). Binding to Mac-1 is however favored if ICAM-1 carries oligomannose *N*-glycans rather than complex-type *N*-glycans ([@ref20]). Neuraminidase treatment of transfected L-cells expressing human ICAM-1 does not change their interaction with Mac-1 suggesting that it is not the sialylation of complex *N*-glycans that hinders Mac-1 binding. The MIP-2-inducing capacity of murine ICAM-1 in mouse astrocytes (not expressing LFA-1 or Mac-1) strongly depends on its sialylation. Whereas sICAM-1 expressed in CHO cells had potent signaling activity, nonsialylated sICAM-1 expressed in the Lec-2 mutant of CHO cells was much less active ([@ref62]). MIP-2 induction was further reduced if sICAM-1 lacked both sialic acid and galactose, or if it contained only high-mannose-type *N*-glycans. All these glycoforms of mouse sICAM-1 retained a normal ability to bind LFA-1 on lymphocytes. The ligand of sICAM-1 on mouse astrocytes has not been identified. However, the affinity of sICAM-1 containing either sialylated complex-type or oligomannose *N*-glycans for the astrocyte surface did not differ (Ki of roughly 300 nM as measured using a competitive radioligand binding assay), suggesting that there was no direct involvement of the sialylated sICAM-1 glycans in binding. The kinetics of the MIP-2 induction were clearly different with fully sialylated sICAM-1 inducing a more rapid, more pronounced and more persistent MIP-2 response than ICAM-1 containing oligomannose *N*-glycans ([@ref74]). Thus, the intensity and kinetics of signaling induced by sICAM-1 in astrocytes was regulated by the completeness of N-glycosylation and in particular of sialylation.

Platelet endothelial cell adhesion molecule-1 {#sec10}
---------------------------------------------

PECAM-1 ([Table II](#TB2){ref-type="table"}*)* is concentrated at the cell--cell junctions of endothelia. Homophilic interactions between PECAM-1 on neighboring endothelial cells play important roles in the formation and regulation of endothelial cell junctions ([@ref15]). PECAM-1 is also involved in the transmigration of leukocytes across endothelial junctions ([@ref59]; [@ref90]). The major binding sites in homophilic PECAM-1 interactions lie in the first N-terminal Ig-like domain and involve five charged amino acids (Asp11, Asp33, Lys50, Asp51 and Lys89), but the second Ig-like domain is also required for binding ([@ref63]). Homophilic interactions occur between PECAM-1 molecules present on the same cell (clustering) as well as on opposing cells. In spite of 79% homology at the amino acid level ([@ref94]), mouse and human PECAM-1 do not bind to each other ([@ref84]; [@ref83]). Indeed, 18 amino acids that differ between human and mouse PECAM-1 are located within the IgD1-homophilic binding interface and include N25, which carries an N-glycan in human PECAM-1 ([@ref63]).

PECAM-1 from mouse lung homogenates contains α2,6-sialylated glycans, which are required for its homophilic binding and binding is inhibited by linear, sialylated oligosaccharides containing Neu5Gc or Neu5Ac in α2,6-linkage ([@ref42]).

PECAM-1 on human pulmonary microvascular endothelial cells (HPMECs) carries α2,6-sialylated glycans ([@ref46]). Sialylation was found to be important for the ability of HPMECs to form capillary-like tubes in matrigel, an in vitro surrogate for one of the key processes in angiogenesis. EC tube formation was inhibited upon NEU1 expression and restored upon ST6GAL1 overexpression.

Recently, the role of sialylation of human PECAM-1 for its homophilic binding was investigated more closely. Presence of α2,6-linked sialic acid on PECAM-1-Fc chimera appeared to inhibit binding to PECAM-1-expressing REN cells ([@ref50]). Based on in-silico docking studies of α2,6- and α2,3-sialylated lactosamine to the crystal structure of the first two Ig domains of human PECAM-1, it was proposed that sialic acid in α2,6-linkage to the N57-glycan could provoke an "autoinhibition" of the PECAM-1 molecule by an intradomain electrostatic interaction with Lys89. In contrast, an α2,3-linked sialic acid on the N25-glycan could bind to the Lys89 of the opposing PECAM-1 thus reinforcing homophilic binding. In such a model, the binding sites of the glycans containing sialic acid in either α2,3- or α2,6- linkage differ, even though they both comprise the Lys89 that engages into electrostatic interactions with sialic acid, either on the same or an opposing PECAM-1 molecule. Deletion of the N25-glycan on PECAM-1 of REN cells did not affect homophilic binding or endothelial barrier function under steady state conditions; it however slowed down the recovery of the endothelial barrier after thrombin treatment.

Vascular endothelial growth factor receptor-2 {#sec11}
---------------------------------------------

VEGFR2 is primarily expressed on endothelial and hematopoietic cells. It is a tyrosine kinase receptor of VEGF-A and importantly involved in the regulation of angiogenesis, vascular development and vascular permeability ([@ref77]; [@ref23]; [@ref43]) ([Table II](#TB2){ref-type="table"}). Its seven Ig-like domains are heavily N-glycosylated ([@ref12]). The VEGFR2 of HUVEC cells was shown to predominantly carry α2,6-sialylated glycans. Such sialylation was important in supporting binding of the VEGF-A~165~ isoform, but not of the VEGF~121~ isoform that lacks the cationic heparin-binding domain ([@ref14]). Pretreatment with *Sambucus nigra* agglutinin or neuraminidase reduced VEGF-A~165~ binding and VEGFR2 autophosphorylation. Interestingly, silencing of the ST6Gal1 gene was accompanied by a compensatory upregulation of ST3Gal1 expression and increased α2,3-sialylation. VEGFR2 carrying α2,3-sialylated glycans was well able to bind VEGF-A~165~. Only concomitant silencing of ST6Gal1 and ST3Gal1 abolished VEGF-A~165~-induced autophosphorylation of VEFR2. It thus seems that only the negatively charged sialic acid, but not its stereochemical presentation, was important to support VEGFR2 activation by VEGF-A~165~.

Lymphatic vessel endothelial hyaluronan receptor-1 {#sec12}
--------------------------------------------------

LYVE-1 is primarily expressed by lymphatic endothelial cells (LEC; [Table II](#TB2){ref-type="table"}). It has long been known as a receptor for HA and is closely related to the HA receptor CD44 of leukocytes ([@ref3]). More recent studies have revealed that it preferentially binds large, polyvalent HA-protein complexes ([@ref33]; [@ref45]). Thus, LYVE-1 may primarily function as a lymphatic trafficking receptor that mediates docking of HA-coated leukocytes to lymphatic vessels ([Figure 1B](#f1){ref-type="fig"}) ([@ref45]; [@ref36]).

The ability of LYVE-1 to bind HA is regulated by the degree of its sialylation ([@ref60]). When expressed on glycosylation mutants of CHO cells, those lacking sialic acid on both *N*- and *O*-glycans (Lec-2 cells) showed strongly increased binding to HA, whereas the cells expressing glycoproteins that carry normal *O*-glycans but only nonsialylated oligomannose *N*-glycans (as expressed by Lec-1 cells) showed reduced binding. It thus appears that the two complex-type *N*-glycans---including their sialylation---on the HA-binding domain are rather supportive of HA binding, whereas the sialylated *O*-glycans present in the membrane-proximal domain hinder HA binding. For HA binding to occur, LYVE-1 needs to be present in clusters ([@ref45]). It was thus proposed that sialylation of the membrane-proximal *O*-glycans hinders LYVE-1 self-association and clustering and thus also HA binding ([@ref60]; [@ref34]). Sialylation of the LYVE-1 stalk region may therefore allow for the regulation of the avidity of LYVE-1 for its ligand HA.

Taken together {#sec13}
==============

Many of the cellular and molecular interactions in which sialylation plays a regulatory role occur in the vascular system. These are on the one hand cell--cell contacts in which very specific glycan- or glycopeptide structures are directly bound by GBPs. In these bindings, molecular properties such as sialic acid substituents and the linkage to the underlying glycan, the identity of the neighboring monosaccharides as well as side chains of the underlying peptide are of key importance. The most famous and best investigated examples are the glycan epitopes related to sLe^x^ (that may also include nearby amino acid side chains) present on leukocytes that are recognized by endothelial P- and E-selectin. Also, the interaction of CLEC-2 expressed on platelets and DC with podoplanin on lymphatic endothelia most likely depends on direct binding of sialylated core-1 *O*-glycans. On the other hand, there are various examples in which sialylation plays more modulatory roles and in which the more general, biophysical properties of sialic acid appear to be important. The MIP-2 production induced by soluble ICAM-1 in mouse astrocytes is most intense and prolonged if sICAM-1 is sialylated. Its affinity for the unknown receptor on astrocytes is however not higher than the affinity of nonsialylated sICAM-1 with poor MIP-2 inducing capacity. Thus, the dynamics and intensity of the signaling elicited appears to be altered if sICAM-1 is sialylated. Binding of VEGF-A~165~ by the VEGFR2 is enhanced if the receptor is sialylated. It does however not matter whether sialic acid is α2,6- or α2,3-linked. This suggests that it is not sophisticated stereo-electronic features, but the global negative charge of the sialoglycan that is important to support binding to the positively charged heparin-binding domain of VEGF-A~165~. The negative charges of sialylated mucin-type *O*-glycans in the stalk region of LYVE-1 were proposed to hinder clustering of LYVE-1-molecules at the cell surface through electrostatic repulsion. As a consequence, HA binding is hindered due to a loss in avidity. With the current analytical methods, it is hardly possible to characterize the biophysical impact of sialylation on the overall biological properties of a glycoconjugate in mechanistic detail. Therefore, such roles of sialylation remain less well defined than those that involve direct binding. As a consequence, they are only rarely described in review articles. The present text was aimed at paying its tribute to these "orphan functions" of sialylation thus adding an additional facet to the abundant review literature on sialic acid.
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